Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics

This article was originally published in PharmAsia News

Executive Summary

Merck KGaA has committed up-front payments and research funding of up to $10 million to Archemix to collaborate on the development and commercialization of first-in-class aptamer-based drugs to treat cancer

You may also be interested in...



Pfizer Invests In Potential New Drug Class

Aptamer therapeutics act like biologics but are chemically synthesized, according to Pfizer collaborator Archemix.

Merck KGaA Builds On Diabetes Portfolio With DPP-IV Inhibitor

Merck signs licensing agreement for Phase II DPP-IV inhibitor with Glenmark.

Merck KGaA Strengthens Its Biotech Presence With Serono Acquisition

Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC065626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By